Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.

Honda Y, Aruga T, Yamashita T, Miyamoto H, Horiguchi K, Kitagawa D, Idera N, Goto R, Kuroi K.

Jpn J Clin Oncol. 2015 May 15. pii: hyv067. [Epub ahead of print]

PMID:
25981620
2.

Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.

Inoue K, Kuroi K, Shimizu S, Rai Y, Aogi K, Masuda N, Nakayama T, Iwata H, Nishimura Y, Armour A, Sasaki Y.

Int J Clin Oncol. 2015 May 13. [Epub ahead of print]

PMID:
25967286
3.

Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer.

Tsurutani J, Kuroi K, Iwasa T, Miyazaki M, Nishina S, Makimura C, Tanizaki J, Okamoto K, Yamashita T, Aruga T, Shigekawa T, Komoike Y, Saeki T, Nakagawa K.

Cancer Sci. 2015 Jun;106(6):734-9. doi: 10.1111/cas.12658. Epub 2015 Apr 9.

PMID:
25786335
4.

Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients.

Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M.

Int J Clin Oncol. 2015 Mar 14. [Epub ahead of print] No abstract available.

PMID:
25772578
5.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group.

N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.

PMID:
25693012
6.

Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients.

Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M.

Int J Clin Oncol. 2015 Feb 10. [Epub ahead of print]

PMID:
25666483
7.

Pressure-sensitive reaction yield of the TePixD blue-light sensor protein.

Kuroi K, Okajima K, Ikeuchi M, Tokutomi S, Kamiyama T, Terazima M.

J Phys Chem B. 2015 Feb 19;119(7):2897-907. doi: 10.1021/jp511946u. Epub 2015 Jan 28.

PMID:
25601594
8.

[Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].

Ito Y, Masuda N, Iwata H, Mukai H, Horiguchi J, Tokuda Y, Kuroi K, Mori A, Ohno N, Noguchi S.

Gan To Kagaku Ryoho. 2015 Jan;42(1):67-75. Japanese.

PMID:
25596682
9.

Transient conformational fluctuation of TePixD during a reaction.

Kuroi K, Okajima K, Ikeuchi M, Tokutomi S, Terazima M.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14764-9. doi: 10.1073/pnas.1413222111. Epub 2014 Sep 29.

10.

Comparison of outcomes between women with de novo stage IV and relapsed breast cancer.

Kitagawa D, Horiguchi S, Yamashita T, Kuroi K, Shimizu K.

J Nippon Med Sch. 2014;81(3):139-47.

11.

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.

Masuda N, Higaki K, Takano T, Matsunami N, Morimoto T, Ohtani S, Mizutani M, Miyamoto T, Kuroi K, Ohno S, Morita S, Toi M.

Cancer Chemother Pharmacol. 2014 Aug;74(2):229-38. doi: 10.1007/s00280-014-2492-y. Epub 2014 May 29.

PMID:
24871032
12.

Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.

Ando M, Yamauchi H, Aogi K, Shimizu S, Iwata H, Masuda N, Yamamoto N, Inoue K, Ohono S, Kuroi K, Hamano T, Sukigara T, Fujiwara Y.

Breast Cancer Res Treat. 2014 Jun;145(2):401-9. doi: 10.1007/s10549-014-2947-1. Epub 2014 Apr 12.

PMID:
24728578
13.

Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study).

Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M.

Breast Cancer Res Treat. 2014 May;145(1):143-53. doi: 10.1007/s10549-014-2907-9. Epub 2014 Mar 30.

PMID:
24682674
14.

Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG.

Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F.

Breast Cancer. 2014 Feb 27. [Epub ahead of print]

PMID:
24574277
15.

Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG.

Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F.

Breast Cancer. 2013 Dec 14. [Epub ahead of print]

PMID:
24338638
16.

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy.

Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M.

Breast Cancer Res Treat. 2013 Nov;142(1):69-80.

17.

Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.

Ueno T, Masuda N, Yamanaka T, Saji S, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Sasano H, Toi M.

Int J Clin Oncol. 2014 Aug;19(4):607-13. doi: 10.1007/s10147-013-0614-x. Epub 2013 Oct 8.

PMID:
24101215
18.

Anomalous diffusion of TePixD and identification of the photoreaction product.

Kuroi K, Tanaka K, Okajima K, Ikeuchi M, Tokutomi S, Terazima M.

Photochem Photobiol Sci. 2013 Jul;12(7):1180-6. doi: 10.1039/c3pp25434h.

PMID:
23535998
19.

An overview of the Japan Breast Cancer Research Group (JBCRG) activities.

Ohno S, Kuroi K, Toi M.

Breast Cancer. 2013 Oct;20(4):291-5. doi: 10.1007/s12282-012-0420-8. Epub 2013 Mar 15. Review.

20.

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.

Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, Srimuninnimit V, Tokuda Y, Kuroi K, Iwase H, Inaji H, Ohsumi S, Noh WC, Nakayama T, Ohno S, Rai Y, Park BW, Panneerselvam A, El-Hashimy M, Taran T, Sahmoud T, Ito Y.

Breast Cancer. 2014 Nov;21(6):703-14. doi: 10.1007/s12282-013-0444-8. Epub 2013 Feb 13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk